Literature DB >> 19239230

Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.

Birgitte W Lund1, Anne Eeg Knapp, Fabrice Piu, Natalie K Gauthier, Mikael Begtrup, Uli Hacksell, Roger Olsson.   

Abstract

We recently discovered the isoform selective RAR beta 2 ligand 4'-octyl-4-biphenylcarboxylic acid (3, AC-55649). Although 3 is highly potent at RAR beta 2 and displays excellent selectivity, solubility issues make it unsuitable for drug development. Herein we describe the exploration of the SAR in a biphenyl and a phenylthiazole series of analogues of 3. This ultimately led to the design of 28, a novel, orally available ligand with excellent isoform selectivity for the RAR beta 2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19239230     DOI: 10.1021/jm801532e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Amelioration of Diabetic Nephropathy Using a Retinoic Acid Receptor β2 Agonist.

Authors:  Steven E Trasino; Xiao-Han Tang; Maria M Shevchuk; Mary E Choi; Lorraine J Gudas
Journal:  J Pharmacol Exp Ther       Date:  2018-07-27       Impact factor: 4.030

Review 2.  Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs.

Authors:  Farnaz Fouladi; Kristine J Steffen; Sanku Mallik
Journal:  Bioconjug Chem       Date:  2017-03-08       Impact factor: 4.774

3.  A Retinoic Acid β2-Receptor Agonist Exerts Cardioprotective Effects.

Authors:  Alice Marino; Takuya Sakamoto; Xiao-Han Tang; Lorraine J Gudas; Roberto Levi
Journal:  J Pharmacol Exp Ther       Date:  2018-06-15       Impact factor: 4.030

4.  Probing biological activity through structural modelling of ligand-receptor interactions of 2,4-disubstituted thiazole retinoids.

Authors:  Hesham Haffez; David R Chisholm; Natalie J Tatum; Roy Valentine; Christopher Redfern; Ehmke Pohl; Andrew Whiting; Stefan Przyborski
Journal:  Bioorg Med Chem       Date:  2018-02-10       Impact factor: 3.641

Review 5.  Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review.

Authors:  Alan D Borthwick; Maria B Goncalves; Jonathan P T Corcoran
Journal:  Bioorg Med Chem       Date:  2020-07-29       Impact factor: 3.641

6.  Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.

Authors:  Maria B Goncalves; Earl Clarke; Christopher I Jarvis; S Barret Kalindjian; Thomas Pitcher; John Grist; Carl Hobbs; Thomas Carlstedt; Julian Jack; Jane T Brown; Mark Mills; Peter Mumford; Alan D Borthwick; Jonathan P T Corcoran
Journal:  Bioorg Med Chem Lett       Date:  2019-02-11       Impact factor: 2.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.